PT4007777T - Células car t contra bcma para o tratamento de mieloma múltiplo - Google Patents

Células car t contra bcma para o tratamento de mieloma múltiplo

Info

Publication number
PT4007777T
PT4007777T PT207575440T PT20757544T PT4007777T PT 4007777 T PT4007777 T PT 4007777T PT 207575440 T PT207575440 T PT 207575440T PT 20757544 T PT20757544 T PT 20757544T PT 4007777 T PT4007777 T PT 4007777T
Authority
PT
Portugal
Prior art keywords
car
treatment
multiple myeloma
cells against
against bcma
Prior art date
Application number
PT207575440T
Other languages
English (en)
Original Assignee
Hospital Cli­Nic De Barcelona
Univ Barcelona
Fundacioderecercaclinicbarcelona Inst Dinvestigacionsbiomediquesaugustpi I Sunyer Frcb Idibaps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital Cli­Nic De Barcelona, Univ Barcelona, Fundacioderecercaclinicbarcelona Inst Dinvestigacionsbiomediquesaugustpi I Sunyer Frcb Idibaps filed Critical Hospital Cli­Nic De Barcelona
Publication of PT4007777T publication Critical patent/PT4007777T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
PT207575440T 2019-08-02 2020-08-03 Células car t contra bcma para o tratamento de mieloma múltiplo PT4007777T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19382673 2019-08-02

Publications (1)

Publication Number Publication Date
PT4007777T true PT4007777T (pt) 2024-01-12

Family

ID=67658496

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207575440T PT4007777T (pt) 2019-08-02 2020-08-03 Células car t contra bcma para o tratamento de mieloma múltiplo

Country Status (18)

Country Link
US (1) US12509525B2 (pt)
EP (2) EP4272837A3 (pt)
JP (1) JP7729561B2 (pt)
AU (1) AU2020325690A1 (pt)
CA (1) CA3148930A1 (pt)
DK (1) DK4007777T5 (pt)
ES (1) ES2971033T3 (pt)
FI (1) FI4007777T3 (pt)
HR (1) HRP20240037T1 (pt)
HU (1) HUE064890T2 (pt)
LT (1) LT4007777T (pt)
PL (1) PL4007777T3 (pt)
PT (1) PT4007777T (pt)
RS (1) RS65094B1 (pt)
SI (1) SI4007777T1 (pt)
SM (1) SMT202400013T1 (pt)
WO (1) WO2021023721A1 (pt)
ZA (1) ZA202201166B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243771A1 (en) * 2022-02-09 2023-08-17 Hadasit Medical Research Services And Development Ltd. CAR ANTI-BCMA TO TARGET IMMUNITY-RELATED DISORDERS, COMPOSITIONS AND RELATED METHODS
EP4378953A1 (en) * 2022-12-02 2024-06-05 Universitat de Barcelona Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2025141187A1 (en) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1994026290A1 (en) 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
NO3051026T3 (pt) 2011-10-21 2018-07-28
JP6694712B2 (ja) * 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
KR102632731B1 (ko) * 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
SG10202012157QA (en) * 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
CN108004259B (zh) 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
ES2953362T3 (es) 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Also Published As

Publication number Publication date
ES2971033T3 (es) 2024-06-03
JP2022542443A (ja) 2022-10-03
AU2020325690A1 (en) 2022-03-03
HUE064890T2 (hu) 2024-04-28
HRP20240037T1 (hr) 2024-03-29
EP4272837A3 (en) 2024-02-28
US12509525B2 (en) 2025-12-30
WO2021023721A1 (en) 2021-02-11
ZA202201166B (en) 2022-10-26
EP4007777B1 (en) 2023-10-11
SMT202400013T1 (it) 2024-03-13
JP7729561B2 (ja) 2025-08-26
LT4007777T (lt) 2024-02-12
DK4007777T3 (da) 2024-01-15
FI4007777T3 (fi) 2024-01-11
SI4007777T1 (sl) 2024-03-29
PL4007777T3 (pl) 2024-03-11
RS65094B1 (sr) 2024-02-29
EP4007777A1 (en) 2022-06-08
EP4272837A2 (en) 2023-11-08
CA3148930A1 (en) 2021-02-11
US20220267459A1 (en) 2022-08-25
DK4007777T5 (da) 2024-08-05

Similar Documents

Publication Publication Date Title
IL256056A (en) Ezh2 inhibitors for treating lymphoma
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
IL256209A (en) Novel cannabinoid combination therapies for multiple myeloma (mm)
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
PT3562486T (pt) Uso de dexmedetomidina sublingual para o tratamento da agitação
IL253945B (en) kdm1a inhibitors to treat the disease
ZA202006610B (en) Compositions for the treatment of skin conditions
PT3377516T (pt) Composição para o tratamento do cancro
IL279260A (en) KDM1A inhibitors for the treatment of diseases
EP3267995A4 (en) INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF FIBROSIS
UY37018A (es) Inhibidores bicíclicos de pad4
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
DK3452050T3 (da) Composition comprising hmos for the treatment of noninfectious diarrhoea
ZA202007055B (en) Compositions for the treatment of skin conditions
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
HUE054271T2 (hu) Mielóma Multiplex (MM) kezelése
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
LT3886799T (lt) Kompozicija, skirta plaukų slinkimo gydymui
PT4007777T (pt) Células car t contra bcma para o tratamento de mieloma múltiplo
IL282700A (en) Heterocyclic compounds for the treatment of epilepsy
EP3626256C0 (fr) Composition pour le traitement des lésions tissulaires
IT201600109507A1 (it) Composizione per il trattamento preventivo o curativo dei disturbi epatici
PT4296670T (pt) Derivados de ácido sulfopropanoico para tratamento de distúrbios neurodegenerativos